The Information : VC Fundraising Just Can’t Keep Up

VC Fundraising Just Can’t Keep Up


The sky’s the limit for valuations for companies like SpaceX, but the venture firms writing the checks have less money in total to spend.

Recent data from PitchBook shows how steep the decline in cash is. Fund managers raised $45.7 billion in new funds in the first nine months of the year. At that pace, fundraising is headed for the lowest level since 2017.

The number of new funds, meanwhile, is on track to be the lowest in at least a decade. There were just 376 new funds in the first nine months of the year, less than half of the 832 for all of last year and a steep drop from the 1,776 funds launched in 2022.

It isn’t necessarily shocking that the limited partners in VC funds are growing skittish. The majority of venture funds formed between 2017 and 2024 had yet to see a single public listing or sale, portfolio management company Carta said earlier this year. The timing of these funds meant that they largely missed the 2021 liquidity boom, with startups too young to make money in that banner IPO year.

Last year, VC funds recovered after two years of negative returns in aggregate, according to a report by Cambridge Associates. “While the last year has been one of recovery for the private markets, the aftershocks of the 2021 era continue to reverberate,” said Cambridge, predicting that the “distribution drought” and “fundraising slowdown” to continue into 2026.

This hasn’t stopped new firms from entering the picture. For example, comms guru Lulu Cheng Meservey recently raised $40 million to launch her first venture fund. Max Gazor recently left CRV to start a new firm, Striker Venture Partners.

Despite challenges, we are seeing some large new funds form, particularly those that had exits in recent years. Andreessen Horowitz is in the process of raising over $10 billion in new funds and Tiger Global Management is raising more than $2 billion.

What’s more, there has been a rebound in acquisitions this year. Tech mergers are on track for their biggest year since 2021.

Initial public offerings are slowly coming back. In fact, as I reported Friday, SpaceX is working toward a listing in the second half of next year. But there won’t likely be enough money returned from IPOs to satisfy VC funds’ backers. I expect venture funds to continue to rely on so-called secondaries, or the sale of existing shares, to return cash to their investors.

The Information : Arista Is the AI Data Center Networking Stock to Watch

Arista Is the AI Data Center Networking Stock to Watch

The Takeaway
  • Arista’s AI revenue projected to nearly double to $2.75 billion next year.
  • Microsoft and Meta drive significant demand for Arista’s AI networking.
  • Company’s 64% gross margin exceeds rivals, signaling strong profitability.


All the data centers hastily going up around the country for AI need networking pipes and software for moving data around. A few companies specialize in selling the networking gear, but one company, Arista Networks, stands out as undervalued on Wall Street.

Arista has a much higher gross margin—64%—than rival Celestica, whose margin is only 11%. The two companies have been growing at the same rate, although Celestica is projected to grow a bit faster next year. That might explain why Arista is trading at 40 times next year’s expected earnings, a key valuation metric, while Celestica is at about 44, according to S&P Global Market Intelligence. But Arista has the potential to grow faster than it has projected, which makes it the better bet for investors.

Arista is one of a few companies that will benefit indirectly from the AI revolution as a result of big tech firms’ massively expanded capital expenditures for new data centers.

Arista’s biggest customers, for instance, are Microsoft and Meta Platforms, which accounted for 20% and 15% of its sales in 2024, respectively. Both companies have been vocal about their plans to increase spending on data centers for AI. Meta, for one, is on track to lift its spending on capex this year to as high as $72 billion, up more than $30 billion on what it spent in 2024. Its executives said in October that its spending in 2026 would grow by a dollar amount “notably larger” than in 2025. A chunk of the increased spending from both Meta and Microsoft should show up in Arista’s top line over the next two years.

And that’s not all. Arista’s chief financial officer, Chantelle Breithaupt, said last week at an investment conference that the company is working on networking systems for at least four large customers—likely including Microsoft and Meta—which are building out their own AI data centers, each containing over 100,000 GPUs. Broadly speaking, the more AI chips in a data center, the more data it processes—and that requires more switches, such as the ones Arista sells, to move that data around.

In addition to those projects, the company also says it has 30 to 40 other customers it is working with in its AI data center business, including “neocloud” customers, which rent out data centers full of graphics processing units to AI firms.

AI-related revenue is a small but fast-growing portion of the cloud business. Last year, Arista executives didn’t provide a breakdown of how much revenue came from its fledgling AI business, but this year the company expects to make $1.5 billion from that segment—about 17% of the total—nearly doubling to a projected $2.75 billion next year, when it will be 26% of the total.

Arista’s problem is that the rest of its revenue is barely growing. The company generates most of it from selling networking hardware to other firms for use in traditional cloud data centers. It also installs networking gear and related software in office buildings and other workplaces. It has forecast rapid growth from office sales, a smaller and newer business than traditional data centers, where growth is sluggish.

As a result, even with the surge in AI and office building revenue, the company only expects revenue to grow a projected 20% to 22%, which is lower than the anticipated 27% growth rate this year.

A Conservative Approach

Arista bulls have a simple explanation for why they’re not worried about the company’s apparent revenue slowdown next year: Arista’s projections are always too low.

In recent years, its revenue growth has exceeded its executives’ initial guidance by anywhere between 9 and 19 percentage points, according to UBS hardware analyst David Vogt.

With that in mind, Vogt thinks Arista has a strong chance of beating the 2026 revenue target its executives outlined. He suggested that the company would likely raise its guidance in February to reflect that possibility, adding that it hasn’t done so yet because AI revenue is so new for Arista that it’s not yet clear exactly how long customers will take to formally sign off on new installments, which is necessary for the company to recognize that revenue.

“Based on every metric that we track, along its supply chain, its balance sheet, inventory, purchase commitments, et cetera…they’re going to kill that [2026 AI revenue] number,” he said.

Another indicator of Arista’s promise is the 87% year-over-year increase in deferred revenue for the nine months to September, which amounts to $4.7 billion the company expects to generate but has not yet recognized. The strength of that pipeline suggests Arista’s projection that it will grow its top line by 20% in 2026 to $10.5 billion could be an underestimate.

Then there’s its fat gross profit margin, largely due to Arista selling systems it designs and builds on its own. Celestica, on the other hand, co-develops more of its hardware and software in tandem with its customers, which means it can’t keep as large a share of the profits.

To some observers, a recent sell-off of Arista stock presented a buying opportunity. Arista shares fell 16% after its third-quarter earnings call last month, when its executives projected its fourth-quarter revenue would be roughly in line with the $2.3 billion it generated in the third quarter.

“The guidance implies nothing beyond the fact that management bears a cautious view as to its ability to supply demand, in our view,” Morningstar analyst William Kerwin wrote in a report last month, noting that he is optimistic about the firm’s ability to “increase supply more quickly and beat its targets as it’s done in the past.

“Investors should be comfortable with the high multiple on the stock given the immense growth opportunity before the firm, as well as its market dominance,” Kerwin wrote.

WSJ : Hinge CEO Leaves to Start an AI-Driven Dating App

Hinge CEO Leaves to Start an AI-Driven Dating App
Veteran marketer Jackie Jantos takes the reins as Justin McLeod shifts focus to Overtone, with Match Group support

  • Justin McLeod is stepping down as Hinge CEO to launch Overtone, an AI-driven dating app supported by Match Group.
  • Match Group said it plans to lead Overtone’s initial funding round in early 2026 and maintain a substantial ownership position.
  • Jackie Jantos, president and chief marketing officer of Hinge, has been named to succeed McLeod as CEO.

Match Group said Hinge founder Justin McLeod is stepping down as chief executive of the unit to launch Overtone, an AI-driven dating app in the early stages of development.

McLeod will remain as an adviser to Hinge through March, the company said, adding that McLeod and a team spent much of 2025 developing Overtone and that the company fully supports it.

Jackie Jantos, president and chief marketing officer of Hinge, has been named to succeed McLeod as CEO.

Match, which owns the dating apps Hinge, Tinder and its namesake dating brand, has been trying to gain traction with younger users and contending with fewer users willing to pay for premium features on dating apps.

Jantos joined the company as its chief marketing officer four years ago from password-management firm Dashlane, where she held the position of chief marketing officer after stints at Spotify and Coca-Cola.

Hinge during her time at the marketing helm shifted focus to zero in on a Gen Z audience—one often characterized as lonely and lovesick. She headed up marketing pushes like “No Ordinary Love,” a campaign inspired by the boom in romance literature that published original love stories on Substack, on the walls of New York City subway cars and in a zine.

Jantos in 2023 began a marketing push ostensibly encouraging young people to get off their phones and embrace real-life activities. In March 2024, the company published a physical book of things to do without a screen. Jantos was promoted to the role of president a year later.


Match recently said third-quarter results improved, but forecast a potentially slower fourth quarter as it experiments with user-experience tests. Tinder experienced a 7% drop in paying users, Match said, but Hinge generated an increase of 17%.

The company said it plans to lead Overtone’s initial funding round in early 2026 and to hold a substantial ownership position. Match Group CEO Spencer Rascoff is expected to join Overtone’s board, and McLeod is expected to be the chair. Overtone will operate independently, Match said.

Tamika Young, Hinge’s senior vice president of global communications, was named chief marketing and communications officer at Hinge.

>>> Vol Dispersion Monitor : Inditex, LVMH, Prosus, Sanofi, Siemens, VW

  • Biggest IV-RV spread premiums:
    • Wolters Kluwer (YTD: -43.7%; RSI: 34); IV 30.6 vs RV 22.7 with vol dispersion of 7.4; IV in the 88th percentile
    • Sanofi (YTD: -7.3%; RSI: 36); IV 23 vs RV 15.7 with vol dispersion of 6.8; IV in the 44th percentile
    • VW (YTD: +27.9%; RSI: 78); IV 26.1 vs RV 19.4 with vol dispersion of 6.2; IV in the 23rd percentile
    • LVMH (YTD: -0.7%; RSI: 48); IV 24.3 vs RV 17.8 with vol dispersion of 6; IV in the 4th percentile
    • Prosus (YTD: +34.9%; RSI: 26); IV 26 vs RV 19.8 with vol dispersion of 5.7; IV in the 13th percentile
  • Biggest IV-RV spread discounts:
    • Bayer (YTD: +88.9%; RSI: 77); IV 28.7 vs RV 66.6 with vol dispersion of -38.3; IV in the 4th percentile
    • Siemens Energy (YTD: +135.1%; RSI: 60); IV 42.9 vs RV 73.6 with vol dispersion of -31.2; IV in the 11th percentile
    • Inditex (YTD: +13.2%; RSI: 72); IV 18.4 vs RV 40.2 with vol dispersion of -22.2; IV in the 11th percentile
    • Siemens (YTD: +27.1%; RSI: 54); IV 23.8 vs RV 42.3 with vol dispersion of -19; IV in the 11th percentile
    • Rheinmetall (YTD: +168.4%; RSI: 54); IV 35.6 vs RV 53.5 with vol dispersion of -18.4; IV in the 7th percentile

Le Figaro : «Budget de la Sécu, la potion tragique de l’Assemblée»

«Budget de la Sécu, la potion tragique de l’Assemblée»

Sébastien Lecornu brandit comme une victoire son budget de la Sécurité sociale, mais l’honnêteté tout comme l’inquiétude qu’inspire le délitement de notre pays obligent à considérer ce moment comme une défaite collective.

Les amateurs de tambouille parlementaire - s’il en reste quelques-uns - goûteront avec un brin d’admiration la recette de Maître Lecornu. Un bouillon de socialisme, un bloc central coupé en morceaux, une pincée d’écolos, un bouquet de LR, des Horizons émincés : faire mijoter quelques semaines, et la soupe est prête. Potion tragique au regard de nos finances publiques, mais il faut bien passer l’hiver…

Le premier ministre, on le comprend, brandit comme une victoire son budget de la Sécurité sociale, mais l’honnêteté tout comme l’inquiétude qu’inspire le délitement de notre pays obligent à considérer ce moment comme une défaite collective. La France n’est pas une île ; l’Assemblée n’est pas une principauté. Ce dont on discute depuis trois mois est en décalage total avec les urgences d’une nation surendettée et déclassée. Les prédateurs se partagent le monde, la France décourage ses forces vives. « Travailler moins pour gagner un peu moins », « imposer plus pour dépenser plus » sont les devises de cet exercice budgétaire.

Le PS et la droite LR, brancardiers d’un macronisme déjà condamné
Les effets économiques de ce marchandage sont catastrophiques. Ils consistent, en balançant à la Seine la réforme des retraites, en jouant sans vergogne à « qui veut taxer des milliards ? », à stabiliser le naufrage.
Les effets politiques ne sont pas plus glorieux. L’Assemblée s’est changée en gigantesque conseil général, en foirail où l’on négocie le bout de gras tout en laissant planer le spectre d’une dissolution en cas de défection. Au bout du compte, trop de députés défendent leur intérêt particulier, à très court terme, tout en embouchant, sans vergogne, le clairon de l’intérêt national.

Un choix tactique fascinant a poussé le Parti socialiste et la droite LR à se faire les brancardiers d’un macronisme déjà condamné. Voter le budget avec François Hollande, s’abstenir avec les amis de Sandrine Rousseau, c’est donc la perspective qu’ont décidé d’ouvrir les troupes de Laurent Wauquiez et d’Édouard Philippe. Tout ce petit monde fait corps pour s’enfermer ensemble dans une impasse. Pendant ce temps, l’autoroute est grande ouverte pour Jean-Luc Mélenchon et Jordan Bardella. La stabilité à tout prix, c’est l’antichambre du chaos.

WSJ : Massive Debt-Fueled Deals Are Back on Wall Street

Massive Debt-Fueled Deals Are Back on Wall Street
Paramount’s $77.9 billion bid for Warner—backed by $54 billion in debt—is making some bond investors queasy

  • Big-ticket mergers and acquisitions, valued at $10 billion or more, reached a record dollar amount this year, largely financed by debt.
  • Paramount’s hostile bid for Warner Bros. Discovery included $54 billion in committed debt financing, impacting Warner’s bond prices.
  • Financing options from corporate-bond, syndicated-loan, and private-credit markets are fueling large, debt-heavy deals.

The megadeal is back and so is Wall Street’s immense appetite for debt.

Paramount’s hostile bid for Warner Bros. Discovery WBD 3.78%increase; green up pointing triangle this week, the leveraged buyout of gaming company Electronic Arts earlier this year and other recent debt-laden transactions have all been possible thanks to a spike in lending by banks and even some private-credit funds.

Big-ticket mergers and acquisitions, or those valued at $10 billion or more, hit a record dollar amount this year, according to Dealogic. Much of the price tag on those deals gets paid for with debt.

Debt-heavy deals mean large paydays for shareholders but also more risks for bond investors when credit markets are showing signs of overexuberance. And would-be acquirers have more choices than ever: The corporate-bond, syndicated-loan and private-credit markets are all whirring at the same time.

“These big, bolder bets are becoming more interesting, and people are willing to try them because of the financing that’s available,” said Matthew Toole, director of deals intelligence at the London Stock Exchange Group.

Expectations that the Trump administration will be more accommodating to large tie-ups are also pumping the size of deals up to record levels. Paramount’s offer for Warner included $54 billion in committed debt financing from Bank of America, Citigroup and the investment firm Apollo Global Management. Netflix’s NFLX -0.08%decrease; red down pointing triangle featured $59 billion, backed by Wells Fargo, BNP Paribas and HSBC.

Disclosure of the financings triggered a trading frenzy in Warner’s bonds, with about $450 million changing hands on Monday after Paramount PSKY 0.48%increase; green up pointing triangle formally announced its hostile takeover plan, according to data from MarketAxess. Bond prices have dropped about 5% in December, largely because the Paramount bid relied more heavily on debt than analysts had expected, fund managers who own the debt said.

The debt load will likely escalate if the bidding war continues. That is particularly worrying because excessive borrowing played a big part in Warner’s past financial troubles, the fund managers said.

It was formed in 2022 when AT&T spun out its WarnerMedia unit to merge with a smaller firm, Discovery, a deal that saddled the prevailing company with about $50 billion in debt. Warner worked to whittle down that debt load, cutting costs relentlessly and putting cash flow toward debt payments.

A merger with Paramount would strain its balance sheet once again. But Paramount executives said Monday on a call announcing their hostile bid that they plan to turn the combined Warner-Paramount into an investment-grade company by finding billions in cost cuts. They expect Warner-Paramount’s debt to become investment grade in two years.

Debt investors are quick to point out that deals rarely go according to plan, especially the scope of planned cost savings.

“In hindsight, media acquisitions have not gone that great,” said Jawad Hussain, a director at S&P Global Ratings specializing in media and entertainment companies. S&P initially expected it would raise its rating of Warner when the Discovery deal was announced but ended up cutting it when the merged company failed to hit projections made at the time of the merger.

Warner picked Netflix’s offer in part because of uncertainty about how solid Paramount’s financing is, especially if debt markets seize up as they did in 2022, a person with knowledge of the deal said. While Paramount’s bid relies on a broad coalition of lenders and equity partners—and the equity is backstopped by the family of billionaire Larry Ellison and private-equity firm RedBird Capital—Netflix can go it alone thanks to its piles of cash and investment-grade single-A credit rating, he said.

Wall Street banks have mostly avoided big debt deals since being stuck in 2022 with a series of so-called hung deals, or loans they kept on their books rather than selling them to investors at a loss. The most notable? The $13 billion in borrowings for Elon Musk’s leveraged buyout of Twitter. That debt sat on banks’ balance sheets for over two years because of the social-media company’s lagging performance (the last of the debt was sold by banks earlier this year).

Earlier this year, a group of investors including Saudi Arabia’s Public Investment Fund and Silver Lake unveiled the largest leveraged buyout ever, a roughly $55 billion take-private of Electronic Arts, the maker of videogames including Madden NFL and the Sims. That deal included $20 billion in debt financing.

At Goldman Sachs’s financial-services conference on Monday, bankers voiced confidence the deal machine will keep humming along—even, they said, the big ones that require a lot of financing. Clients are eager to get more scale, expand technology and offset tariff cost increases. Goldman’s finance chief said the long-awaited private-equity deal boom might be starting, an area that relies heavily on debt.

“I think for the most part there is general confidence and optimism,” Moelis CEO Navid Mahmoodzadegan said at the New York conference. “My outlook for overall M&A activity is quite, quite good going into next year.”

Those 2026 buyouts are sure to add to a debt pile that’s already high enough to leave some bond investors feeling queasy.

FT : Biotech rally mints huge profits for hedge funds

Biotech rally mints huge profits for hedge funds
Wave of M&A fuels rally as big pharma groups hunt for blockbusters ahead of patent cliff

Hedge funds betting on drugs stocks have made bumper profits this year, as a recent wave of deals by big pharmaceutical companies drives the biggest rally in the biotechnology sector in a decade.

New York-based investment manager Perceptive Advisors has seen its flagship $4.5bn hedge fund soar 75 per cent this year to the end of November, according to people who had seen the numbers. Meanwhile, Caligan Partners, another New York-based hedge fund, which manages more than $1bn, was up 92 per cent, its best year since inception in 2022.

The gains come as the Nasdaq Biotechnology index has soared by about one-third, its strongest year since 2014. It has been helped by a renewed surge in dealmaking as big groups looking for their next blockbuster drug spend billions of dollars on biotech companies at the forefront of innovation.

“Every week or two there is a new multibillion-dollar M&A transaction announced, and that has been going on for six months,” said one hedge fund executive who is active in the sector. “The speed at which they keep happening is kind of amazing.”

Healthcare-focused funds more broadly have been the best performing in the hedge fund industry this year, returning 36 per cent from January 1 to the end of November, with 19 per cent of those gains coming from the past two months alone, according to data from PivotalPath. It has been the best year for the strategy since 2013.

“These are unheard of numbers,” said Jon Caplis, PivotalPath’s founder and chief executive.

Large pharmaceutical companies are facing a particularly large so-called patent cliff where their blockbuster drugs come off patent and lose exclusivity, opening the door to competition from generic drugmakers. Drugs with annual revenue of about $180bn are going off patent in 2027 and 2028, roughly 12 per cent of the global market, according to Evaluate Pharma data, with almost every large company affected.

This has driven a number of big pharmaceutical businesses to hunt for smaller groups with promising treatments, often still in clinical trials, with the US Trump administration appearing to be more permissive of deals than the Federal Trade Commission under former president Joe Biden.

Pfizer won a dramatic takeover battle against Novo Nordisk for weight-loss start-up Metsera in November, clinching a deal worth up to $10bn.

Merck spent $10bn on lung disease-focused biotech Verona Pharma in July, its biggest acquisition in two years, amid concerns it has few alternatives that can match the substantial sales figures of cancer drug Keytruda, which loses its patent in 2028.

Both Perceptive and Caligan held positions in Verona and profited from its deal, with the share price soaring about 130 per cent this year.

Perceptive also benefited from bets on US biotech groups Praxis Precision Medicines and Celcuity, whose share prices have surged roughly 250 per cent and 700 per cent, respectively, this year. In October, Praxis released positive results of a trial for a drug to address shaking caused by nervous system issues, while Celcuity announced a successful trial of its cancer drug.

Perceptive and Caligan declined to comment.

Novartis’s heart medication Entresto lost its patent this summer. It agreed a $12bn deal to buy Avidity Biosciences, a company that specialises in treatments for rare diseases, in October.

The patent cliffs that are coming are significant and people are expecting the M&A cycle to continue,” said Sean Conroy, an analyst at Shore Capital.

This year’s profits mark a turnaround for some hedge funds after a tough start to 2025.

The share prices of biotech companies were hit earlier this year by fears that the appointment of Robert F Kennedy Jr — a prominent critic of mainstream medicine — as US health secretary could hit drug approvals. The Trump administration also cut government spending on health research to a 10-year low, which — combined with higher borrowing costs than when many had previously raised money — threatened to put some companies out of business.

Perceptive was down for 2025 by April, according to people familiar with its performance. But the wave of M&A that took place in the second half of the year helped drive a recovery.

FT : Meloni’s party seeks to double limit for cash payments in Italy

Meloni’s party seeks to double limit for cash payments in Italy
Opponents of proposal to increase cap to €10,000 say it would reward tax evaders and illegal business

Italian Prime Minister Giorgia Meloni’s party has been accused by critics of promoting tax evasion with its plan to double the legal limit for cash payments to €10,000.

In a draft amendment to next year’s budget — which must be approved by December 31 — lawmakers from Meloni’s Brothers of Italy have called for legalising cash transactions of up to €10,000, provided that a flat €500 “special stamp duty” is paid on any cash amount over €5,000. 

Brothers of Italy lawmakers say their proposal will enable greater spending on luxury goods by foreign tourists — who sometimes arrive in Italy with large amounts of cash — and help black money return into circulation in the legal economy. 

“We believe that there is a significant amount of cash in Italy for a long time that can be injected into the real, legal economy with a small contribution of €500 that we will tax on the expenditure,” Marco Osnato, chair of the finance committee in the lower house of parliament, told the FT.

Senator Matteo Gelmetti, one of the bill’s main sponsors and a member of the senate budget committee, said the higher cash transaction cap would help foreign visitors who come to Italy as well as the hotels, restaurants and shops that serve them.

He also claimed that it was “a way for the state to raise money”, though he declined to estimate the potential gains. “We’re a highly touristic nation and we know there are a large number of tourists — especially from certain backgrounds — for whom cash is the norm,” Gelmetti said.

Finance minister Giancarlo Giorgetti of the League, one of the parties in Meloni’s coalition, has yet to publicly express an opinion on the amendment’s pros and cons, an assessment that will strongly influence its prospects for adoption. 

However, opposition parties say the scheme would merely reward tax evaders and those involved in illegal businesses, who could spend their undeclared or ill-gotten earnings by paying only a minor tax.

“It’s a strange idea. We consider it a desperate measure to raise money,” said Senator Antonio Misiani of the centre-left Democrat party, adding that only “criminals and mafia” were likely to take advantage of such offers.

Parliament member Angelo Bonelli, of the Alleanza Verdi e Sinistra or Green and Left Alliance, called the measure a “direct favour to tax evaders, an incentive for the black economy, a step backward in the fight against illegality”.

As part of its anti-money laundering efforts, the EU has introduced a Europe-wide €10,000 cap on cash payments in business transactions, a limit that takes effect on Jan 1 2027. But Brussels also allows member states to establish lower cash transaction limits if they so choose. 

In recent years, Italian reformers — including former Prime Minister Mario Draghi — have tried to discourage cash use and promote digital payments as part of a crackdown on Italy’s vast underground economy and rampant tax evasion.

But Meloni’s Brothers of Italy and its allies in the League and Forza Italia draw strong support from small business owners who chafe at Italy’s tax burdens. Among Meloni’s first moves after taking office three years ago was the raising of Italy’s legal limit on cash transactions for businesses from €1,000 to the current €5,000.

Meloni also tried to scrap the legal requirement for small businesses to accept digital payments, and wanted to allow them to demand cash for transactions below €60, but she was forced to backtrack after Brussels warned that such a move was counter to Italy’s pledge to promote digital payments and put the country’s public finances on a sounder footing.

According to a recent estimate by official statistics agency Istat, Italy’s “non-observed” or underground economy was valued at €217bn in 2023, equivalent to 10.2 per cent of GDP, and up 7.5 per cent in value terms from 2022. 

Of the underground economy, some €20bn were revenues from illegal activities, while the rest were from activities that were ostensibly legal but taking place outside the tax net, including employment of unregistered workers in enterprises, and undeclared rents paid in cash, Istat said in its October report.

FT Lex : Netflix’s WBD bid is an antitrust drama without a villain

Netflix’s WBD bid is an antitrust drama without a villain
Expect lawyers to home in on the definition of ‘relevant market’ that best suits their argument

Supermarkets, bank branches, best-selling books, barrels of oil — these are just a few of the markets that have vexed competition lawyers and judges over the decades. The battle for US media empire Warner Bros Discovery will pose a whole new set of questions — with no easy answers — about the way households parcel out their TV spending and their brain space.

Netflix’s bid for WBD was trumped on Monday by a rival cash offer from Paramount Skydance. The interloper contends, in support of its offer, that a Netflix merger would trigger a lengthy and possibly unsuccessful antitrust review. The logic is persuasive. George Mason University law professor John Yun cites data showing Netflix and WBD have 31 per cent of streaming subscriptions and account for 35 per cent of hours watched.

But there are other ways to slice the cake. In antitrust probes, identifying the “relevant market” is critical, and contentious. Include Google’s YouTube as a streaming rival, and Netflix and WBD fall to just 20 per cent of viewing time, according to Nielsen. Include all TV, and they’re just 9.3 per cent. Expect lawyers to home in on the definition that best suits their case.

In a rational world, what matters is whether consumers risk being worse off. Could Netflix use its boosted market clout to dramatically crank up the prices of its enlarged streaming subscriptions? Or charge nosebleed fees to broadcast rivals for WBD content such as Harry Potter and Friends, leading them to jack up their own prices?

Maybe, but not because of simple market share. This isn’t bank branches or supermarkets, where a local monopoly can leave consumers with a Hobson’s choice. Those who balk at Netflix and HBO Max can defect to Amazon, Disney+ or Paramount+, among others. Netflix is big, but Roku or Peacock are as easy to sign up for. Share of eyeballs makes little odds.

What does make a difference is the films and shows themselves — specifically, how good they are. That’s why YouTube isn’t really a substitute for Netflix at all. Sure, it has no end of stuff for a viewer to point their pupils at. But if the relevant market is “stuff you watch for the plot”, Netflix and WBD might indeed have a very large share of the market.

The catch is that such subjective things are much harder to gauge. One option is to look at how much companies splurge on content, as a proxy for the quality of their output. Netflix and WBD may spend $38bn next year, analysts reckon. But Paramount and WBD weigh in at a hefty $32bn. In overall content spend, Comcast beats them all, according to KPMG data, and Walt Disney is close behind.


Years from now, all of this may be moot. Artificial intelligence already hints at a world where movies no longer require a studio, or human actors. YouTube — used by 84 per cent of Americans, according to Pew Research Center — could take on traditional studios one day, armed with its $3.8tn parent’s game-changing AI models. The same might apply to Facebook owner Meta Platforms or OpenAI.

That’s a tomorrow problem, of course. Antitrust judges tend to focus instead on the market as it is, so Netflix will need to sharpen its pencils. But there are two conclusions. If simple viewing time doesn’t equate to market power, then the streaming colossus’ bid for WBD might not be as problematic as it sounds. And however this drama shakes out, the next wave of media innovation could produce a very different set of anti-heroes.

>>> US After Hours Summary: BRZE +14.7% higher on earnings; GEV +6% higher on ra

After Hours Summary: BRZE +14.7% higher on earnings; GEV +6% higher on raised multi-year guidance, dividend hike and buyback increase; CBRL -9.5%, AVAV -5.1%, CASY -2.5% lower on earnings

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings/guidance: BRZE +14.7%, GEV +6% (guidance; also increases dividend and buyback program), PLAY +1.9%

Companies trading higher in after hours in reaction to news: MRVI +5.7% (Director bought 100,000 shares at $3.67-3.70 worth ~$369K), SOL +2.1% (results of extraordinary general meeting), FLR +2% (awarded the Highland Valley Copper Mine Life Extension project), GPRK +1.9% (engagement with Parex Resources; also mid-term adjusted EBITDA guidance), PRAX +1.1% (completion of a Type C metting with FDA), MCHB +1% (FITB enters agreement to acquire Mechanics Bank's (MCHB) Delegated Underwriting and Servicing business line), MA +0.4% (increases dividend; also approves $14 bln share repurchase program), MRVL +0.3% (introduces Golden Cable initiative), AMRX +0.3% (FDA approval for epinephrine injection in single and multi-dose vials), TTC +0.3% (authorizes repurchase up to 6 mln shares), O +0.2% (increases dividend), SMCI +0.1% (expansion of NVDA Blackwell architecture portfolio), ACHR +0.1% (completes first phase of its Hawthorne Airport transactions)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance: LAKE -20.2%, CBRL -9.5%, AVAV -5.1%, CASY -2.5%, BLLN -1.9%

Companies trading lower in after hours in reaction to news: AGRO -13.9% (stock offering), DNLI -8.9% (stock offering), SMX -7.3% (amendment to equity purchase agreement), LGN -4.4% (stock offering by selling shareholders), MIAX -1.9% (stock offering by selling shareholders), MUSA -0.7% (mixed shelf offering), DIS -0.1% (appoints former AAPL exec as new independent director)